Vertical: CNMBase Year: 2025
Market Size (2025)
$122.94M
Projected (2032)
$173.11M
CAGR (2022–2032)
5.0%
Key Players
8+
Market Overview
The Global Avilamycin Market was valued at USD 122.94 Million in 2025 and is projected to reach USD 173.11 Million by 2032, expanding at a CAGR of 5.01% during 2026–2032. Over the historic period the market grew from USD 106.14 Million in 2022 to USD 117.06 Million in 2024, and the forecast adds an absolute value of USD 50.17 Million between 2025 and 2032.
Avilamycin is an orthosomycin antibiotic produced by fermentation and used almost exclusively in animal feed. Its principal commercial roles are the prevention and control of necrotic enteritis caused by Clostridium perfringens in broiler chickens and the control of post-weaning diarrhoea associated with Escherichia coli in pigs. Because the orthosomycin class has no counterpart in human medicine, avilamycin occupies a distinct position in livestock antimicrobial programmes at a time when regulators are restricting the use of antibiotics that are shared with human medicine. Demand is therefore shaped as much by regulation and stewardship policy as by the underlying growth of poultry and pig production.
Key Findings
Livestock: Poultry is the largest segment with USD 73.76 Million in 2025 (60.00% share), and it is also the fastest-growing segment at a CAGR of 5.69% over 2026–2032.
Physical Form: Premix leads with USD 98.35 Million in 2025 (80.00% share), and it is also the fastest-growing form at a CAGR of 5.28%.
Region: Asia Pacific is the leading region with USD 67.62 Million in 2025 (55.00% share), while Middle East & Africa is the fastest-growing region at a CAGR of 6.35%.
Country: China is the leading country with USD 31.10 Million in 2025, while Saudi Arabia is the fastest-growing country at a CAGR of 7.76%, followed by India at 7.39%.
Segmentation Summary
By livestock, the market is divided into Poultry, Swine and Others. Poultry accounted for USD 73.76 Million in 2025 and is expected to reach USD 108.71 Million by 2032, reflecting the central role of avilamycin in necrotic enteritis programmes for broilers. Swine contributed USD 36.88 Million in 2025 and is forecast to grow at 4.00%, supported by the need to manage enteric disease in weaned piglets. The Others segment, covering rabbits and other minor species, was valued at USD 12.29 Million in 2025.
By physical form, Premix dominated with USD 98.35 Million in 2025, because avilamycin is overwhelmingly delivered through medicated feed manufactured by feed mills and integrators. The Others form, which includes granulated and oral powder presentations, was valued at USD 24.59 Million in 2025 and is projected to grow at 3.86%.
Competitive Landscape Summary
The market is consolidated around Elanco Animal Health, the originator of avilamycin, which markets the molecule under brand names including Surmax, Maxus, Inteprity and Kavault and produces the active ingredient at its Speke site in the United Kingdom. A second tier comprises Chinese fermentation-based producers such as Hebei Shengxue Dacheng Pharmaceutical, Guangdong Cocan Bio-Pharmaceutical and Hangzhou Well Sunshine Biotech, regional formulators such as NITA-FARM in Russia and Rooyan Darou in Iran, and Huvepharma, which received US approval in April 2025 for a monensin and avilamycin combination medicated article for broilers. Competition centres on regulatory approvals, label claims, combination use with ionophore anticoccidials, product quality and security of supply.
Challenges and Opportunities
The principal challenge is the continued tightening of antimicrobial regulation. The European Union has prohibited antibiotics as growth promoters since January 2006 and, from September 2026, has applied the same requirement to imports of animal products, suspending Brazilian poultry and beef shipments when guarantees were not provided. China withdrew growth-promoting drug feed additives from 2020 and lists avilamycin premix as a veterinary prescription drug, and India has introduced restrictions for export-oriented poultry. Retailer programmes for meat raised without antibiotics and the expanding range of non-antibiotic alternatives add further pressure.
At the same time, the same regulatory trend creates opportunities. Avilamycin is permitted where several other antimicrobial growth promoters are being withdrawn; Brazil's 2026 ban on bacitracin and virginiamycin as performance enhancers left avilamycin among the permitted products. Generic and combination approvals, new product registrations in Russia and other Eurasian markets, and rapid growth in poultry production across India, Southeast Asia, the Middle East and Africa offer additional room for expansion.
Future Outlook
The market is expected to add USD 50.17 Million in value between 2025 and 2032. Growth will be led by poultry applications in Asia Pacific, Latin America and the Middle East & Africa, while North America and Europe are expected to grow more slowly under prescription-based and therapeutic use models. Over the forecast period the market is expected to shift further from growth promotion towards veterinarian-directed prevention and control, and products with clear disease-specific labels, robust residue data and reliable supply are best placed to gain.
The Avilamycin Market market is projected to grow at a CAGR of 5.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Avilamycin is an oligosaccharide antibiotic of the orthosomycin class produced by fermentation of Streptomyces viridochromogenes. The commercial substance consists mainly of the components avilamycin A and avilamycin B. It inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome and is active principally against Gram-positive bacteria, including Clostridium perfringens. Avilamycin is poorly absorbed from the gastrointestinal tract and acts mainly within the gut. It is administered orally through feed, typically as a premix containing 10% (100 g/kg) avilamycin or as granulated and powder formulations.
For the purpose of this study, the Global Avilamycin Market includes:
Avilamycin premixes and Type A medicated articles used to manufacture medicated feed
Granulated, oral powder and other non-premix avilamycin formulations for oral use
Products used in poultry (broilers, turkeys and replacement pullets), swine and other species such as rabbits
Market value measured at the manufacturer and supplier level
The study excludes:
Other antibiotics and anticoccidials, including the value of ionophores in combination medicated articles
Non-antibiotic feed additives such as probiotics, prebiotics, phytogenics, organic acids and enzymes
The value of complete compound feed into which avilamycin premixes are incorporated
Any human pharmaceutical use
Scope of the Study
The study covers the global market for avilamycin, segmented as follows:
By Livestock: Poultry, Swine, Others
By Physical Form: Premix, Others
By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, with country-level coverage within each region
Timeline: Historic years 2022–2024, base year 2025, forecast period 2026–2032
Unit: Market value in USD Million
Research Objectives
To estimate and forecast the size of the global avilamycin market in value terms for 2022–2032
To analyse the market by livestock and by physical form, and to identify the largest and fastest-growing segments
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and the Middle East & Africa
To evaluate the effect of antimicrobial regulations, including restrictions on growth promoters and prescription requirements, on avilamycin demand
To examine drivers, restraints, opportunities and trends linked to necrotic enteritis control in poultry and enteric disease management in swine
To assess the threat from substitute products, including other antibiotics, anticoccidial programmes, vaccines and non-antibiotic feed additives
To map the value chain from fermentation to medicated feed and end users
To profile the competitive environment and track key developments by leading companies since 2022
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process that combined secondary research, primary research and analytical modelling. The process began with the definition of the market and its segmentation, followed by the collection of data on avilamycin product registrations, livestock production, feed manufacturing and regulatory developments. Market estimates were then developed through top-down and bottom-up approaches, validated through discussions with industry participants and triangulated to arrive at final values for the base year. Forecasts were built from the base year using an assessment of demand drivers, regulatory change and competitive dynamics.
Secondary Research
Secondary research was used to build an understanding of the product, its applications, its regulatory status and the structure of demand. The main types of sources included:
Industry associations: feed manufacturer, poultry and pork producer associations, and animal health industry bodies, for production, feed output and policy information
Government and regulatory bodies: the U.S. Food and Drug Administration, the Canadian Food Inspection Agency, the European Medicines Agency and the European Commission, the Ministry of Agriculture and Rural Affairs of China, Brazil's Ministry of Agriculture and Livestock, and India's Department of Animal Husbandry and Dairying and Food Safety and Standards Authority
Agricultural statistics agencies: livestock production, meat output and trade statistics published by national and international agricultural bodies
Company filings and publications: annual reports, quarterly results, product labels, registration documents and press releases of avilamycin manufacturers and suppliers
Trade journals and scientific literature: poultry, swine and feed industry publications, and peer-reviewed studies on necrotic enteritis, post-weaning diarrhoea and antimicrobial resistance
Paid databases: trade, company and regulatory databases used to cross-check product approvals, company data and trade flows
Primary Research
Primary research was conducted through in-depth interviews with participants across the value chain to validate secondary findings, refine assumptions and capture current market conditions.
Supply side: executives, product managers and technical service managers at avilamycin manufacturers, premix formulators and distributors of veterinary medicated feed additives
Demand side: nutritionists and veterinarians at poultry and swine integrators, feed mill managers, and independent livestock veterinarians
Objectives: to validate market size and segment splits, understand usage practices and dosing programmes, assess pricing and procurement patterns, and gauge the expected impact of regulatory changes and alternative products
Market Size Estimation
Top-down approach: The overall market was estimated from the value of the medicated feed additive and in-feed antibiotic market, from which the share attributable to avilamycin was derived using product registration data, company revenue indicators and expert inputs. The resulting value was then allocated across regions, livestock types and physical forms.
Bottom-up approach: Country-level estimates were built from livestock populations and production volumes, the proportion of animals receiving avilamycin, typical inclusion rates and treatment durations, and average selling prices. Country values were aggregated to regional and global totals.
Data triangulation: The results of the two approaches were compared and reconciled, and the final estimates were validated through primary interviews. Where differences arose, assumptions on usage rates, pricing and segment shares were re-examined until the estimates converged.
Forecasting Methodology
Forecasts were developed from the base year using a factor-based approach. The main factors considered were:
Projected growth in poultry meat and pork production by country
The incidence and management of necrotic enteritis and post-weaning diarrhoea
Changes in antimicrobial regulation, including bans on growth promoters, prescription requirements and import requirements for animal products
Adoption of substitute products and antibiotic-free production programmes
Pricing trends, generic entry and the availability of supply
Each factor was assessed for its direction and strength of impact over the forecast period, and the resulting growth rates were applied to segment, regional and country estimates and checked for consistency with the global total.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Market values are expressed in nominal US dollars, and exchange rate effects are assumed to be stable over the forecast period
Regulatory frameworks in force in 2025 and announced changes are assumed to be implemented as published
No major disruption to avilamycin active ingredient supply is assumed over the forecast period
Livestock disease outbreaks such as avian influenza or African swine fever are assumed to follow historical patterns without extraordinary disruption
Revenue data for several manufacturers are not publicly disclosed, and their positioning is assessed qualitatively
Avilamycin sales are often reported within broader animal health or feed additive categories, which limits direct verification of product-level revenue
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Avilamycin Market is consolidated. Elanco Animal Health, which introduced avilamycin worldwide in 1987 and reports its use in more than 40 countries, holds the leading position through its originator brands, regulatory approvals in major markets and its own fermentation site at Speke in the United Kingdom. The rest of the market is served by a small number of fermentation-based producers in China, by regional formulators and registration holders in Russia, Iran and other markets, and by Huvepharma, which entered the US market with a generic combination approval in 2025. Competition in regulated markets such as the United States, Canada and the European Union is driven by approvals, label claims, combination use with anticoccidials and technical service. In emerging markets, generic premixes compete more directly on price and availability, and local registration holders play an important role in distribution.
Key Player Positioning
Market leader
Elanco Animal Health (United States): The originator and global leader, with the brands Surmax, Maxus, Inteprity and Kavault and approvals for broilers and swine in the United States, Canada, South Africa, Russia and other markets. Elanco reported total revenue of USD 4,715 million for fiscal year 2025, including Farm Animal revenue of USD 2,362 million, of which poultry accounted for USD 858 million and swine for USD 379 million. The company reacquired its Speke active ingredient site in November 2024 to secure supply of key farm animal products.
Challengers
Huvepharma (Bulgaria): A privately held animal health and nutrition company with a large ionophore and feed additive portfolio. It received US approval in April 2025 for Coxidin (monensin) and Inteprity (avilamycin) Type A medicated articles for broilers and is expanding its fermentation capacity, including an agreement in July 2026 to acquire Euroapi Italy. Revenue is not publicly disclosed; group sales of more than BGN 770 million were reported for 2022.
Hebei Shengxue Dacheng Pharmaceutical (China): A state-owned fermentation-based producer of antibiotics, feed additives and premixes, part of China National Uranium Corporation, listing avilamycin among its main products and planning an avilamycin premix line at its Inner Mongolia base. Revenue is not separately disclosed.
Niche and regional players
Guangdong Cocan Bio-Pharmaceutical (China): Manufacturer of Avilamaks avilamycin oral powder, registered in Russia in July 2025 through VETPROM.RU. Revenue is not publicly disclosed.
Hangzhou Well Sunshine Biotech (China): Export-oriented manufacturer of veterinary products and feed additives offering avilamycin 10% premix. Revenue is not publicly disclosed.
NITA-FARM (Russia): Saratov-based veterinary drug manufacturer and developer of Avilafor 10% avilamycin powder for pigs and poultry, registered in April 2026. Revenue is not publicly disclosed.
Rooyan Darou (Iran): Human and veterinary pharmaceutical manufacturer supplying avilamycin 10% premix for chickens and turkeys in the Iranian market. Revenue is not publicly disclosed.
GOROS21.RU (Russia): Registration holder of Avilagran avilamycin 10% granules for pigs and poultry, registered in Russia in February 2025. Revenue is not publicly disclosed.
Competitor Dashboard
The dashboard below compares the profiled companies on four qualitative parameters, rated Low, Medium, High or Very High.
Threat of New Entrants: Low
Fermentation-based production requires dedicated capacity, strain development and process know-how
Product registration requires efficacy, safety and residue data, and approval timelines are long in major markets
Tightening antimicrobial regulation reduces the attractiveness of new investment in in-feed antibiotics
Bargaining Power of Suppliers: Medium
Fermentation media inputs are widely available agricultural commodities
Active ingredient supply is concentrated, which gives active ingredient producers leverage over independent formulators
Vertically integrated producers such as Elanco and the larger Chinese manufacturers reduce their own dependence on external suppliers
Bargaining Power of Buyers: High
Large poultry and swine integrators and feed mill groups purchase in volume and negotiate on price
Buyers can switch between avilamycin and other enteric health tools, including other antibiotics and non-antibiotic additives
Veterinarians and nutritionists strongly influence product selection through health programmes
Threat of Substitutes: High
Other in-feed antibiotics remain available in many markets, including bacitracin, enramycin, flavomycin and halquinol where permitted
Ionophore anticoccidials and coccidiosis vaccines reduce the predisposing conditions for necrotic enteritis
Probiotics, phytogenics, organic acids and enzymes are widely used in antibiotic-reduction programmes
Intensity of Competitive Rivalry: Medium
The market has a limited number of active ingredient producers, led by the originator
Generic premixes from Chinese and regional producers compete on price in emerging markets
Competition is shaped more by approvals, label claims and supply reliability than by price alone in regulated markets
Threat of New Entrants: Low; Fermentation capability and regulatory approvals create high entry barriers.
Bargaining Power of Suppliers: Medium; Commodity inputs, but concentrated active ingredient supply.
Bargaining Power of Buyers: High; Large integrators and feed mills with multiple enteric health options.
Threat of Substitutes: High; Other antibiotics, anticoccidials, vaccines and non-antibiotic additives.
Competitive Rivalry: Medium; Few producers, with price competition from generics in emerging markets.
Market estimates by geography (2032)
InsightAsia Pacific leads with $96.56M by 2032, while Middle East & Africa is projected to grow fastest at a 6.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $20.06M | $23.59M | $27.52M | 3.2% | 16% |
| Europe | $4.34M | $5.44M | $7.03M | 4.9% | 4% |
| Asia Pacific | $57.90M | $74.88M | $96.56M | 5.2% | 56% |
| Latin America | $17.72M | $23.32M | $30.64M | 5.6% | 18% |
| Middle East & Africa | $6.11M | $8.35M | $11.36M | 6.4% | 7% |
| Total | $106.14M | $135.58M | $173.11M | 5.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$173.11M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $108.71M | 5.7% | 63% |
| Swine | $48.54M | 4.0% | 28% |
| Others | $15.86M | 3.7% | 9% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Avilamycin Market covering market dynamics, competitive landscape, and strategic outlook.
The Avilamycin Market market is projected to reach $173.11M by 2032, growing at 5.0% CAGR. The Poultry segment holds the largest share.
The Global Avilamycin Market is shaped by two forces that work in opposite directions. Growing demand for poultry meat and pork, and the need to control enteric diseases in intensive production, support the use of avilamycin. At the same time, regulation aimed at reducing antimicrobial use in livestock limits how and where avilamycin can be used. The net effect varies by region: in Europe and North America avilamycin is used under veterinary control for specific disease indications, whereas in parts of Asia Pacific, Latin America and the Middle East & Africa it is also used as a performance enhancer.
Market Growth Factor Analysis
The table below summarises five macro and five micro factors that influence the avilamycin market, the direction of their impact and the strength of that impact in three periods of the forecast. The impact scores are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger effect on the market in the stated direction.
Expansion of Global Poultry Production and the Need for Necrotic Enteritis Control
Poultry has become the largest meat category in global production, supported by its relatively low cost, short production cycle, efficient feed conversion and the absence of religious restrictions on consumption. Production growth is concentrated in large integrated broiler operations in Brazil, the United States, China, India, Southeast Asia and the Middle East. In these systems, necrotic enteritis caused by Clostridium perfringens remains one of the most costly enteric diseases, both in its clinical form, which raises mortality, and in its subclinical form, which reduces weight gain and feed efficiency. Necrotic enteritis is closely linked to coccidiosis, and avilamycin is commonly used alongside ionophore anticoccidials in shuttle and rotation programmes. In the United States, the Inteprity label for broilers covers the prevention of mortality caused by necrotic enteritis, and approved combinations with monensin, salinomycin, narasin and narasin with nicarbazin allow integration into established coccidiosis programmes. As poultry output rises, the number of birds under such programmes increases, directly supporting demand for avilamycin premix.
Shift Towards Antimicrobials Not Used in Human Medicine
Antimicrobial stewardship policies in most major markets distinguish between antibiotics that are important for human medicine and those that are used only in animals. Avilamycin belongs to the orthosomycin class, which has no counterpart in human medicine, and its originator positions it as an animal-use-only antibiotic. When Elanco launched Inteprity in the United States in 2016, it presented the product as an alternative to antibiotics shared with human medicine, dispensed under the Veterinary Feed Directive. This positioning has become more relevant as regulators withdraw shared-class antibiotics from production uses. In April 2026, Brazil's Ministry of Agriculture and Livestock prohibited avoparcin, bacitracin, zinc bacitracin, bacitracin methylene disalicylate and virginiamycin as performance enhancers, while avilamycin remained among the permitted products alongside enramycin, flavomycin and halquinol. Such decisions narrow the set of available in-feed antimicrobials and direct demand towards the molecules that remain authorised.
Management of Post-Weaning Diarrhoea in Swine
Post-weaning diarrhoea associated with Escherichia coli is a major cause of mortality and growth loss in weaned piglets. Two widely used control tools have been restricted in recent years. The European Union ended the use of zinc oxide at medicinal levels in piglet feed in June 2022, and colistin has been restricted or banned for use in livestock feed in several countries, including China and India. Producers have therefore looked for other approved options to manage enteric disease in the post-weaning period. Avilamycin carries swine labels for this indication in several markets: in the United States, Kavault is approved for weaned pigs to reduce the incidence and severity of diarrhoea caused by E. coli, and in Canada the Surmax premix is registered for broilers and for swine with post-weaning E. coli diarrhoea. China, the world's largest pig producer, lists avilamycin premix as a veterinary prescription drug, which allows continued therapeutic use under veterinary oversight.
Industrialisation of Livestock Production in Emerging Markets
Livestock production in India, Southeast Asia, the Middle East, Africa and Latin America is moving from backyard and small-scale systems towards commercial and integrated operations with professional feed mills, veterinary services and structured health programmes. This shift raises the use of medicated feed additives, which are more practical to administer at scale through compound feed. Governments in several of these markets are supporting domestic poultry production as part of food security programmes, including efforts in Saudi Arabia to raise poultry self-sufficiency. In India, the broiler sector is dominated by large integrators that operate their own feed mills, and demand for poultry meat continues to rise with incomes and urbanisation. These trends underpin the higher growth rates of Middle East & Africa, Latin America and Asia Pacific in the forecast, and the strong growth of countries such as Saudi Arabia, India and the UAE.
Generic and Combination Product Approvals
The approval of generic and combination products widens access to avilamycin and integrates it more closely into poultry health programmes. In April 2025, the U.S. Food and Drug Administration approved Huvepharma's Coxidin (monensin) and Inteprity (avilamycin) Type A medicated articles for broilers as an abbreviated application, the first generic version of an avilamycin combination in the United States. Combinations with ionophore anticoccidials allow producers to address coccidiosis and necrotic enteritis together, and further combination and generic approvals in other markets would extend avilamycin use.
Substitution for Withdrawn Growth Promoters
In markets where several antimicrobial growth promoters are being withdrawn but avilamycin remains permitted, producers are likely to shift part of their demand towards the remaining approved products. Brazil's 2026 ban on bacitracin and virginiamycin as performance enhancers is the most significant recent example, given the scale of the Brazilian poultry and pork sectors. Similar reviews in other Latin American, Asian and African markets could produce comparable substitution effects, particularly for producers serving domestic markets.
Registration Expansion in Emerging and Eurasian Markets
New registrations are widening the geographic reach of avilamycin. Several avilamycin products were registered in Russia during 2025 and 2026, including Avilagran granules, Guangdong Cocan's Avilamaks oral powder and NITA-FARM's Avilafor 10% powder. Chinese fermentation producers are also supplying active ingredient and premixes for export. Rising poultry production in India, Southeast Asia, Africa and Central Asia, combined with the development of local registration and distribution networks, offers further room for growth.
Tightening Regulation of Antimicrobial Use in Livestock
Regulators continue to restrict the use of antibiotics in animal production. The European Union has prohibited antibiotics as growth promoters since 1 January 2006, and its veterinary medicines regulation, applicable since January 2022, further restricts preventive use of antimicrobials. China withdrew all growth-promoting drug feed additives other than traditional Chinese medicines from 2020 under MARA Announcement No. 194, and avilamycin premix is now a prescription drug. In the United States, avilamycin products are dispensed under the Veterinary Feed Directive, which requires a veterinarian's order. India has introduced residue limits and bans on specified antimicrobials in food animals and, from July 2025, a ban on antimicrobial growth promoters in export-oriented poultry. Each of these measures reduces the volume of avilamycin used for growth promotion and makes demand more dependent on disease-specific prescribing.
Antibiotic-Free Production and Non-Antibiotic Alternatives
Large food retailers, restaurant chains and processors in North America and Europe have adopted sourcing policies for meat raised without antibiotics or without antibiotics important to human medicine, and some poultry producers market their products as raised with no antibiotics ever. These programmes exclude avilamycin even though it is not used in humans. At the same time, the range of alternatives for gut health has widened to include probiotics, prebiotics, phytogenic additives, organic acids, enzymes, coccidiosis vaccines and improved biosecurity. While these alternatives do not fully replace antibiotics in controlling clinical necrotic enteritis, their adoption limits the growth of avilamycin in mature markets.
Concentrated Active Ingredient Supply
Avilamycin is produced by fermentation, and a large part of global supply depends on a small number of sites. The originator's active ingredient is produced at Speke in the United Kingdom, a site that Elanco sold to the contract manufacturer TriRx in February 2022 and bought back in November 2024 after TriRx's Speke business entered administration. This concentration exposes the market to supply interruptions, and it makes it harder for new formulators to secure qualified active ingredient.
Transition from Growth Promotion to Veterinary-Directed Use
Across major markets, avilamycin is moving from use as a performance enhancer to use as a prescription or veterinary-directed product for specific diseases. This trend is visible in the United States under the Veterinary Feed Directive, in China through the prescription drug catalogue and in the European Union through the veterinary medicinal product framework. As a result, demand is increasingly linked to disease pressure, diagnostic practice and veterinary recommendation rather than routine inclusion in feed.
Focus on Formulation Quality and Granulated Forms
Manufacturers are giving greater attention to particle size, homogeneity and handling properties, which affect mixing uniformity and dust exposure in feed mills. Granulated presentations such as Maxus G100 and Avilagran are offered alongside conventional premixes. Elanco's 2022 communication on avilamycin highlighted product quality and particle size as differentiating factors.
Antimicrobial Resistance Monitoring
Regulators and researchers monitor the susceptibility of target bacteria to avilamycin. A study published in the Journal of Antimicrobial Chemotherapy in 2023 reported no change in avilamycin minimum inhibitory concentrations for Clostridium perfringens in Canada for up to seven years after the approval of Surmax. Continued surveillance will be important to maintain regulatory confidence in the molecule.
Trade-Linked Compliance Requirements
Import requirements are becoming a channel through which antimicrobial rules spread beyond domestic markets. In September 2026, the European Union suspended imports of poultry, beef and other animal products from Brazil after Brazil did not provide guarantees by 3 September 2026 that exported products were produced without growth-promoting antimicrobials. India has similarly banned antimicrobial growth promoters in export-oriented poultry. Exporting producers therefore face pressure to remove growth-promotion uses of avilamycin from export supply chains, even where such use remains legal domestically.
The avilamycin value chain runs from fermentation inputs through active ingredient manufacture and formulation to distribution and use in medicated feed.
Raw materials and inputs: Fermentation media based on carbohydrate and protein sources, mineral salts and process chemicals, together with the Streptomyces viridochromogenes production strain. Carriers and excipients are used later in formulation. Input costs are influenced by agricultural commodity prices and energy costs.
Active ingredient manufacturing: Avilamycin is produced by submerged fermentation followed by extraction, purification and drying. This stage requires specialised fermentation capacity, strain know-how and good manufacturing practice certification, and is concentrated among a small number of producers in the United Kingdom and China.
Formulation: The active ingredient is blended with carriers to produce premixes, typically at 10% (100 g/kg), and granulated or powder formulations. Formulators must meet registration requirements for each market, including stability, homogeneity and residue data.
Distribution and channels: Products reach users through direct sales to integrators and large feed mills, through veterinary distributors and through local registration holders and importers. In many markets a veterinary feed directive or prescription is required before medicated feed can be produced.
End users: Broiler and turkey integrators, swine producers, commercial feed mills that manufacture medicated feed and, to a lesser extent, rabbit and other livestock producers.
North America
United States: Avilamycin is regulated by the FDA Center for Veterinary Medicine under 21 CFR 558.68. Inteprity is approved for broilers to prevent mortality caused by necrotic enteritis associated with Clostridium perfringens, and Kavault is approved for weaned pigs to reduce E. coli diarrhoea. Avilamycin feeds are dispensed under the Veterinary Feed Directive (21 CFR 558.6).
Canada: Avilamycin is listed in the Canadian Food Inspection Agency's Compendium of Medicating Ingredient Brochures. Surmax Premix 100 g/kg is approved for broiler chickens for necrotic enteritis and for swine for post-weaning E. coli diarrhoea.
Europe
Regulation (EC) No 1831/2003 on additives for use in animal nutrition prohibited antibiotics, including avilamycin, as growth promoters from 1 January 2006.
Regulation (EU) 2019/6 on veterinary medicinal products and Regulation (EU) 2019/4 on medicated feed, both applicable since 28 January 2022, govern the therapeutic use of avilamycin and restrict preventive use of antimicrobials. Article 118 of Regulation (EU) 2019/6 extends the ban on growth promotion to animals and products imported into the European Union.
Commission Regulation (EU) No 37/2010 sets maximum residue limits for pharmacologically active substances, including avilamycin, in foodstuffs of animal origin.
United Kingdom: Veterinary medicines, including medicated feed, are regulated by the Veterinary Medicines Directorate under the Veterinary Medicines Regulations 2013.
Asia Pacific
China: MARA Announcement No. 194 (July 2019) withdrew growth-promoting drug feed additives, other than traditional Chinese medicines, from 1 January 2020 and required feed manufacturers to stop producing commercial feed containing them from 1 July 2020. Avilamycin premix is included in MARA's third batch of the veterinary prescription drug catalogue issued in December 2019. MARA's national action plan for reducing the use of veterinary antimicrobials (2021–2025) further promoted reduction.
India: The Ministry of Health and Family Welfare banned colistin for food-producing animals, poultry, aquaculture and animal feed supplements in July 2019. The FSSAI Contaminants, Toxins and Residues First Amendment Regulations, 2024, effective April 2025, prohibit specified antimicrobials in food animal production. Notification S.O. 3226(E) of July 2025 bans antimicrobial growth promoters in export-oriented poultry.
Latin America
Brazil: The Ministry of Agriculture and Livestock (MAPA) prohibited colistin as a growth promoter through Normative Instruction No. 45 (November 2016) and tylosin, lincomycin and tiamulin through Normative Instruction No. 1 (January 2020). Portaria SDA/MAPA No. 1,617 (April 2026) prohibited avoparcin, bacitracin, zinc bacitracin, bacitracin methylene disalicylate and virginiamycin as performance enhancers, while avilamycin remains permitted.
Middle East & Africa
South Africa: Avilamycin products are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947); Surmax 100 is registered under registration number G0930.
International standards: The Codex Alimentarius Commission and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) have evaluated avilamycin residues, providing reference standards that many countries in the region adopt.
Feb 2022: Elanco Animal Health; Divestiture; Completed the sale of its Speke (UK) and Shawnee (Kansas, US) manufacturing sites to contract manufacturer TriRx, with a supply agreement in place.
2022: Huvepharma; Expansion; Established an affiliate in South Korea and a representative office in Ukraine.
2023: Huvepharma; Expansion; Established affiliates in Indonesia and the Philippines.
Sep 2023: NITA-FARM; Expansion; Opened a RUB 140 million workshop for veterinary injectables in Saratov, part-funded by federal and regional industrial development funds.
Jul 2024: Elanco Animal Health; Divestiture; Completed the sale of its aqua business to Merck Animal Health for USD 1.3 billion.
2024: Huvepharma; Expansion; Opened a new vaccine production plant in Razgrad, Bulgaria.
Nov 2024: Elanco Animal Health; Acquisition; Reacquired the Speke manufacturing site from TriRx administration for USD 25 million, securing a key part of its farm animal supply chain.
Feb 2025: GOROS21.RU; Product Registration; Registered Avilagran avilamycin 10% oral granules for pigs and poultry in Russia.
Apr 2025: Huvepharma; Product Approval; Received US FDA approval for Coxidin (monensin) and Inteprity (avilamycin) Type A medicated articles for broilers (ANADA 200-801).
2025: Huvepharma; Expansion; Established an affiliate in Malaysia.
Jun 2025: NITA-FARM; Expansion; Opened an 800 m² laboratory and testing centre for quality control.
Jul 2025: Guangdong Cocan Bio-Pharmaceutical; Product Registration; Avilamaks avilamycin oral powder for pigs and poultry registered in Russia through VETPROM.RU.
Oct 2025: Huvepharma; Financing; Secured a EUR 130 million credit facility to fund research and development investments.
Dec 2025: Hebei Shengxue Dacheng Pharmaceutical; Corporate; Parent company China National Uranium Corporation listed on the Shenzhen Stock Exchange.
Apr 2026: NITA-FARM; Product Registration; Registered Avilafor 10% avilamycin oral powder for pigs and poultry in Russia.
Jul 2026: Huvepharma; Acquisition; Signed an agreement to acquire 100% of Euroapi Italy, including the Brindisi fermentation site, adding about 25% to its fermentation capacity.
Political
Government action plans on antimicrobial resistance are restricting in-feed antibiotic use in major producing countries
Food security policies in the Middle East, Africa and Asia support expansion of domestic poultry production
Trade measures, such as the European Union suspension of Brazilian animal product imports in 2026, link antimicrobial policy to market access
Economic
Feed grain price volatility affects producer margins and willingness to spend on feed additives
Rising incomes in emerging economies increase demand for poultry meat and pork
Generic competition exerts pressure on avilamycin premix prices in price-sensitive markets
Social
Consumer and retailer demand for meat raised without antibiotics limits use in some markets
Public awareness of antimicrobial resistance shapes policy and purchasing decisions
Poultry is accepted across religious and cultural groups, supporting broad demand growth
Technological
Improvements in fermentation yield and purification reduce production costs
Granulated formulations improve mixing uniformity and reduce dust in feed mills
Advances in vaccines, probiotics and diagnostics create alternative or complementary disease control tools
Environmental
Fermentation manufacturing requires energy and generates waste streams subject to environmental regulation
Antimicrobial residues in manure and the environment are subject to increasing scrutiny
Effective control of enteric disease improves feed efficiency, reducing feed use per unit of meat produced
Legal
Product registration, maximum residue limits and withdrawal periods govern market access in each country
Prescription requirements such as the US Veterinary Feed Directive and China's prescription drug catalogue control distribution
Bans on growth promotion uses in the European Union, China and parts of India and Brazil restrict label claims
Profiles of 32 companies operating in the Avilamycin Market market, including revenue, employee count, and market positioning where available.
Showing 32 of 32 companies
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
Company Headquarters: Amsterdam, Netherlands Founded: 1994 Workforce: ~35,200 Company Working: Akzo Nobel N.V. operates its business by manufacturing products of various industries such as decorative paints, automotive & specialty coatings, industrial coatings, powder coating and marine, protective and yacht coatings. The automotive and specialty coatings segment of the business comprises products such as aerospace coatings, consumer electronics coatings, automotive OEM coatings, vehicle refinishes and sign finishes. Further, its industrial coatings segment offers products including coil and extrusion coatings, wood finishes, packaging coatings, and adhesives. The company owns more than 3,100 patents and has robust research and development capabilities which is evident from the fact that it has spent around USD 1.33 billion on research and development in last five years and possess five R&D centers. The brand portfolio offered by the company includes Dulux, Sikkens, International and Interpon and has a strong geographical presence in around 150 countries.
Company Headquarters: Ohio, US Founded: 1866 Workforce: ~ 64,000 Company Working: Sherwin Williams Company specializes in the manufacturing of numerous types of paints and coatings products. The company makes its products available through a chain of over 5,000 stores which are operated by the company and through mass merchandisers, independent paint dealers, home centers, automotive retailers, hardware stores, and industrial distributors across various parts of North America, parts of Europe, China, Australia, and New Zealand. The company serves numerous industries such as transportation, construction, and packaging by offering a wide array of product under brands such as Miniwax, Purdy, Carbot and Krylon, among others. Also, it has around 136 manufacturing and distribution facilities across various geographical regions, further enabling the company to expand their market penetration.
Company Headquarters: Tainan City, Taiwan Founded: 1960 Workforce: ~ 5,000 Company Working: CHIMEI, a leading company in the materials and specialty chemicals industry, has a strategic approach focused on innovation, sustainability, and customer-centricity. The company aims to continuously enhance its position by prioritizing research and development efforts, driving technological advancements, and delivering innovative solutions. CHIMEI emphasizes sustainable practices throughout its operations, integrating environmental stewardship into its production processes and product lifecycle management. By minimizing environmental impact and promoting resource efficiency, CHIMEI strives to contribute to a more sustainable future. The company's strategic direction also revolves around understanding and exceeding customer expectations. CHIMEI actively collaborates with customers to comprehend their specific needs and challenges, offering tailored solutions, technical support, and reliable service. Customer satisfaction is a top priority, and CHIMEI's dedication to delivering superior product quality and exceptional customer service sets it apart in the industry.
58 interactive charts drawn from the Avilamycin Market dataset — market size, each segment breakdown, and every region and country by segment. Open one to read its full data table and download it.
Global Avilamycin Market By Region
Global Avilamycin Market By Livestock
Global Avilamycin Market By Physical Form
Global Avilamycin Market — North America by Country
Global Avilamycin Market — North America by Livestock
Global Avilamycin Market — North America by Physical Form
Global Avilamycin Market — U.S. by Livestock
Global Avilamycin Market — U.S. by Physical Form
Global Avilamycin Market — Canada by Livestock
Global Avilamycin Market — Canada by Physical Form
Global Avilamycin Market — Mexico by Livestock
Global Avilamycin Market — Mexico by Physical Form
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
